Overview

Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy of intravitreal ranibizumab by determining the pathogenesis of macular edema, which cause a direct effect on visual function. In particular, we focus on the correlation between the treatment effectiveness of ranibizumab and the role of the cytokines involved in the cause of macular edema.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tokyo Medical University
Treatments:
Ranibizumab
Criteria
Inclusion Criteria:

- Foveal thickness > 300 μm

- Best corrected visual acuity < 20/30

Exclusion Criteria:

- History of retinal diseases other than BRVO, glaucoma, uveitis, diabetes mellitus,
rubeosis iridis, ocular infections, laser photocoagulation, and intraocular surgery